Company news

Celcuity Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium

December 8, 2022

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

December 6, 2022

Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium

November 21, 2022

Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference

November 9, 2022

Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 9, 2022

Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call

November 2, 2022

Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors

September 13, 2022

Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 10, 2022

Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call

August 3, 2022

Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference

August 2, 2022

Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer

July 17, 2022

Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates

May 15, 2022

Celcuity Inc. Announces $100 Million Private Placement

May 15, 2022

Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call

May 8, 2022

Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences

April 4, 2022

Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates

March 22, 2022

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call

March 15, 2022

Celcuity to Participate in the Cowen 42nd Annual Health Care Conference

March 1, 2022

Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update

January 17, 2022

Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium

December 9, 2021

Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium

December 1, 2021

Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development

November 28, 2021

Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial

November 14, 2021

Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences

November 8, 2021

Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 7, 2021

Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call

October 28, 2021

Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases

October 17, 2021

Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 8, 2021

Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference

August 4, 2021

Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast

August 1, 2021

Celcuity to Participate in the William Blair Biotech Focus Conference

July 7, 2021

Celcuity Announces Pricing of Follow-on Offering

June 27, 2021

Celcuity Announces Launch of Follow-on Offering

June 27, 2021

Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations

June 8, 2021

Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 9, 2021

Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast

April 25, 2021

Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling

April 11, 2021

Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update

April 7, 2021

Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer

April 7, 2021

Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

March 15, 2021

Celcuity Announces Closing of Common Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock

February 28, 2021

Celcuity Prices Upsized Public Offering of Common Stock

February 23, 2021

Celcuity Announces Proposed Public Offering of Common Stock

February 21, 2021

Celcuity Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

February 15, 2021

Celcuity Inc. Schedules Release of Fourth Quarter and Fiscal Year 2020 Financial Results and Conference Call

January 31, 2021

Celcuity Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen

January 26, 2021

Celcuity to Present at the B. Riley Oncology Investor Conference

January 18, 2021

Celcuity Announces Clinical Trial Collaboration with Massachusetts General Hospital and Puma Biotechnology

December 22, 2020

Celcuity Reports Third Quarter 2020 Financial Results and Recent Business Highlights

November 8, 2020

Celcuity Inc. Schedules Release of Third Quarter 2020 Financial Results and Conference Call

October 25, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.